Skip to main content

Advertisement

Table 1 Characteristics of patients, n = 27

From: Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis

  Patient characteristics
Age 48.1 ± 10.0 years
Gender (male) 17 (63.0%)
Caucasian 24 (88.9%)
Smoking history Current 4 (14.8%)
Former 13 (48.1%)
Non-smoker 10 (37.0%)
Scadding stages at initiation of infliximab I 1 (3.7%)a
II 5 (18.5%)
III 4 (14.8%)
IV 17 (63%)
  1. aTreatment indication for infliximab in this patient was severe obstructive pulmonary function caused by endobronchial stenosing